In the next podcast from Johns Hopkins Kimmel Cancer Center Director Dr Bill Nelson, he talks with Dr Trinity Bivalacqua, the Director of Urologic Oncology at the Johns Hopkins Brady Urologic Institute and the Deputy Director of the Johns Hopkins Greenberg Bladder Cancer Institute, about the treatment options for bladder cancer. In this preview,(...)
bladder cancer
Cancer Matters with Dr. Bill Nelson – New Paradigms in the Treatment of Bladder Cancer
Posted by | podcastDr Bill Nelson talks with Dr David McConkey, Director of the Greenberg Bladder Cancer Institute at Johns Hopkins, about the renewed interest in bladder cancer research and the potential for treatment advances in the near future.
The State of the Bladder Cancer Battle
Posted by | Patient StoriesOn a weekend before a business trip, Ken Brothers noticed some blood in his urine. He wondered if it was related his recent loss of 40 pounds on a medically-supervised diet and emailed his doctor about it. Blood in the urine is a common symptom of bladder cancer, but its presence is not always associated(...)
What’s next for bladder cancer research?
Posted by | ResearchThe Johns Hopkins Greenberg Bladder Cancer Institute recently announced a joint effort with the Bladder Cancer Advocacy Network (BCAN) to fund up to two awards totaling $100,000 for young scientists. As part of the announcement, the Institute's director, David McConkey, Ph.D., gave us his thoughts on recent bladder cancer advances and ongoing research. Recent advances, says McConkey, include(...)
ASCO annual meeting features clinical trial results of immunotherapy for bladder and kidney cancer
Posted by | ResearchWith recent FDA approvals of immunotherapy drugs for kidney and bladder cancer, patients now have more options to consider among their treatments. The 2016 ASCO annual meeting featured several new developments in these two cancers that seem to keep the momentum moving forward in this field. We asked Charles Drake, M.D., Ph.D., associate director of(...)
New immunotherapy drug approved to treat bladder cancer
Posted by | treatmentA new immunotherapy drug -- the first in its class -- was approved by the Food and Drug Administration last week for bladder cancer. We asked David McConkey, Ph.D., director of the Johns Hopkins Greenberg Bladder Cancer Institute, to explain the significance of this milestone: "The approval of atezolizumab is arguably the most transformative thing(...)
Symposium Spotlight on Bladder Cancer
Posted by | Uncategorized***This blog is the third in a three-part series on bladder cancer. Read parts one and two. The Johns Hopkins Greenberg Bladder Cancer Institute held its first public symposium with three leading bladder cancer experts providing novel new approaches to managing bladder cancer. “This institute, solely focused on bladder cancer, is the first one of(...)
Bivalacqua Directs Bladder Cancer Advocacy Network Meeting Panel
Posted by | Uncategorized***This blog is the second in a three-part series on bladder cancer. Read part one. Trinity Bivalacqua, M.D., Ph.D., director of urologic oncology in the James Buchanan Brady Urologic Institute and member of the Johns Hopkins Kimmel Cancer Center, co-chaired a panel discussion, “Data Sharing, Privacy Issues and Social Media,” at the Bladder Cancer Advocacy Network’s(...)
Bladder Cancer: No Longer Invisible
Posted by | Uncategorized***This blog is the first in a three-part series on bladder cancer. For too long, bladder cancer has been called the invisible cancer. But a recent convergence of strong philanthropic support and promising research findings are improving awareness and treatment of bladder cancer. Despite being the fifth most common cancer in the United States and(...)